Related Experiment Video
Updated: May 9, 2026
06:17
Osteoclast Derivation from Mouse Bone Marrow
Published on: November 6, 2014
Osteoporosis and cancer.
1Division of Endocrinology, Department of Medicine, College of Medicine, Mayo Clinic, 200 First Street SW, Rochester, MN, 55905, USA, drake.matthew@mayo.edu.
Current Osteoporosis Reports
|July 24, 2013
Summary
Cancer treatments can cause bone loss and fractures. Strategies to protect bone health are crucial for cancer survivors, incorporating therapies and fall prevention, especially for older patients.
Area of Science:
- Oncology
- Bone Metabolism
- Geriatric Medicine
Background:
- Cancer significantly increases the risk of skeletal complications, including bone loss and fractures.
- Cancer therapies, while improving survival, can negatively impact bone cells and density.
- Increased cancer survival necessitates proactive bone health management in patient care plans.
Purpose of the Study:
- To review strategies for mitigating cancer-related bone loss and fracture risk.
- To highlight the effectiveness of antiresorptive therapies in cancer patients.
- To emphasize the need for broader research and guideline adherence beyond common cancers.
Main Methods:
- Review of existing literature on cancer and bone health.
- Analysis of the efficacy of antiresorptive therapies.
- Discussion of nonpharmacologic interventions for fall prevention.
Main Results:
- Antiresorptive therapies are generally effective in reducing bone loss in cancer patients.
- Few studies have fracture risk as a primary endpoint.
- Current patient identification and treatment often do not follow established guidelines.
Conclusions:
- Bone health management is essential for nearly all cancer patients due to improved survival rates.
- Antiresorptive therapies are a cornerstone, but fracture endpoints require more study.
- Nonpharmacologic fall prevention is a vital adjunct, particularly for elderly cancer patients.
Related Concept Videos
01:29Bone Disorders
Aging and its effect on bone remodeling is the most common cause of bone disorders. In young and healthy people, bone deposition and resorption happen at an equal rate to maintain optimal bone health.
Bone deposition is also affected by the levels of sex hormones like estrogen and testosterone that promote osteoblast activity and bone matrix synthesis. When the level of these hormones decreases due to aging, it causes a reduction in bone deposition. As a result, bone resorption by osteoclasts...
Bone deposition is also affected by the levels of sex hormones like estrogen and testosterone that promote osteoblast activity and bone matrix synthesis. When the level of these hormones decreases due to aging, it causes a reduction in bone deposition. As a result, bone resorption by osteoclasts...
01:19Psychoneuroimmunology: Diabetes and Cancer
Chronic stress has been linked to both the onset and progression of serious health conditions, including Type 2 diabetes and cancer. Type 2 diabetes, a widespread chronic illness, is closely associated with obesity and insulin resistance, both of which often worsen under stress. Studies indicate that men experiencing high levels of chronic stress face a 45% higher risk of developing diabetes compared to those with minimal stress. Stress triggers physiological responses that elevate blood...
01:40Bone Remodeling
Bone remodeling is a continuous and balanced process of bone resorption by osteoclasts and bone formation by osteoblasts. In adults, it helps maintain bone mass and calcium homeostasis. While mechanical stress can stimulate turnover as part of the normal maintenance and reparative process, several hormones also regulate bone remodeling.
01:31Osteoclasts in Bone Remodeling
Osteoclasts are cells responsible for bone resorption and remodeling. They originate from hematopoietic progenitor cells present in the bone marrow. Numerous progenitor cells fuse to form multinucleated cells, each with 10-20 nuclei. A single osteoclast has a diameter of 150 to 200 µM. These cells have ruffled borders that break down the underlying bone tissue and release minerals such as calcium into the blood in bone resorption. Osteoclasts cling to bones with their ruffled edges during bone...
03:03mTOR Signaling and Cancer Progression
The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
The mTOR pathway or the...
03:03mTOR Signaling and Cancer Progression
The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
The mTOR pathway or the...